Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) EBT (2019 - 2025)

Historic EBT for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.

  • Innate Pharma's EBT rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 1729.45%. This contributed to the annual value of -$52.9 million for FY2024, which is 54905.28% down from last year.
  • Innate Pharma's EBT amounted to -$25.6 million in Q2 2025, which was up 193.0% from -$48.6 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's EBT registered a high of $7.5 million during Q2 2021, and its lowest value of -$59.1 million during Q4 2022.
  • Moreover, its 5-year median value for EBT was -$25.9 million (2024), whereas its average is -$25.6 million.
  • As far as peak fluctuations go, Innate Pharma's EBT skyrocketed by 27442.65% in 2021, and later plummeted by 432199.99% in 2024.
  • Over the past 5 years, Innate Pharma's EBT (Quarter) stood at -$47.5 million in 2021, then fell by 24.63% to -$59.1 million in 2022, then soared by 89.57% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
  • Its EBT was -$25.6 million in Q2 2025, compared to -$48.6 million in Q4 2024 and -$26.1 million in Q2 2024.